Holen Sie sich die Stockscreener-App
1.49
7.19%
0.10
Handel nachbörslich:
1.49
Schlusskurs vom Vortag:
$1.39
Offen:
$1.4
24-Stunden-Volumen:
479.08K
Relative Volume:
1.08
Marktkapitalisierung:
$134.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.09M
KGV:
-3.6918
EPS:
-0.4036
Netto-Cashflow:
$-26.52M
1W Leistung:
+4.93%
1M Leistung:
+6.43%
6M Leistung:
+26.27%
1J Leistung:
+8.76%
1-Tages-Spanne:
$1.38
$1.515
1-Wochen-Bereich:
$1.35
$1.515
52-Wochen-Spanne:
$0.9228
$1.92
Vivani Medical Inc Stock (VANI) Company Profile
Firmenname
Vivani Medical Inc
Sektor
Branche
Telefon
415-506-8462
Adresse
1350 S. LOOP ROAD, ALAMEDA
Compare VANI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VANI
Vivani Medical Inc
|
1.49 | 127.19M | 0 | -27.09M | -26.52M | -0.4036 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivani Medical Inc Aktie (VANI) Neueste Nachrichten
Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences - Quiver Quantitative
Two New York conferences are planned for Vivani Medical - Stock Titan
Vivani Medical Announces Participation in Upcoming Investor Conferences - globenewswire.com
VANI Stock Price, Quote & Chart - ChartMill
Vivani (VANI) Quarter in Review: EPS Lands Above Forecast in the Latest Session; Trading Response - Vinanet
Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Form 8K Vivani Medical Inc For: 17 August By Investing.com - Investing.com Nigeria
Vivani Medical posts slide presentation under Reg FD; Exhibit 99.1 attached - TradingView
Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market - Bitget
Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold" - MarketBeat
Vivani Medical (NASDAQ: VANI) Completes Full Enrollment In Semaglutide Implant Trial, Strikes Novo Nordisk Deal - foreignpolicyjournal.com
VANI Q1 2026 Earnings: Narrower Loss Slightly Beats Consensus, Shares Rise 4.48%Balance Sheet Strength - vinanet.vn
Vivani Medical Fully Enrolls Phase 1 Semaglutide Implant Trial; Data Due November - Minichart
Form 8K Vivani Medical Inc For: 13 August By Investing.com - Investing.com Nigeria
Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Vivani Medical Q2 losses narrow 41% YoY; signs Novo Nordisk deal - scanx.trade
Vivani Medical: Q2 Earnings Snapshot - Barchart.com
Vivani Medical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027 - Stock Titan
ClearOne (CLRO) details Cortigent reverse merger, 78% Vivani control and new equity plan - Stock Titan
ClearOne to merge with Cortigent, pivoting to neurotech under new Nasdaq ticker - Dealroom
Vivani Medical Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
ClearOne Inc. (CLRO) majority holder cancels warrant as Cortigent merger proceeds - Stock Titan
Form 8K Vivani Medical Inc For: 6 August By Investing.com - Investing.com Nigeria
Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial - marketscreener.com
Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial - TipRanks
Form 8K Vivani Medical Inc For: 6 August - Investing.com India
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - The Manila Times
Semaglutide implant trial doses all 20 participants; data expected in November - Stock Titan
Vivani Medical completes dosing in Phase 1 tria... - pluang.com
ClearOne Cancels 437,500 First Finance Warrants at $5.00 Amid Cortigent Merger Process - TradingView
Vivani Medical (VANI) to Announce Earnings on Wednesday - MarketBeat
Vivani Medical (VANI) Dips 1.54% to $1.28, Holding Within Key $1.22 Support and $1.34 Resistance RangePassive Flow - vinanet.vn
Enterprise value to EBITDA forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Vivani Medical, Inc. Revenue Breakdown – NASDAQ:VANI - TradingView
Form 4 Vivani Medical Inc For: 30 July By Investing.com - Investing.com Nigeria
Vivani Medical (VANI) awards CEO 200K stock options and 100K RSUs - Stock Titan
Vivani Medical (NASDAQ: VANI) grants COO options and performance RSUs - Stock Titan
Vivani Medical (NASDAQ: VANI) awards CFO 75,000 options and RSUs - Stock Titan
Form 4 Vivani Medical Inc For: 28 July - Investing.com India
Form 4 Vivani Medical Inc For: 28 July By Investing.com - Investing.com Canada
Vivani Medical, Inc. (VANI) awards stock options in lieu of director fees - Stock Titan
Vivani Medical (VANI) Slides Nearly 8% as Shares Approach Key SupportPrice Momentum Stocks - dars.gov.et
Vivani Medical Market Sentiment - Benzinga España
Vivani Medical Inc. Revenue Breakdown – FWB:U5P - TradingView
Vivani Medical Inc (VANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - Bernama
Vivani Medical Inc (VANI) Cash Flow - TradingKey
Vivani Medical Inc (VANI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivani Medical Inc (VANI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Finanzdaten der Vivani Medical Inc-Aktie (VANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vivani Medical Inc-Aktie (VANI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Williams Gregg | Director |
Jun 15 '26 |
Buy |
1.26 |
1,587,301 |
1,999,999 |
36,119,086 |
| Williams Gregg | Director |
May 15 '26 |
Buy |
1.26 |
1,587,301 |
1,999,999 |
34,531,785 |
| Williams Gregg | Director |
Apr 15 '26 |
Buy |
1.26 |
1,587,301 |
1,999,999 |
32,944,484 |
| Williams Gregg | Director |
Mar 15 '26 |
Buy |
1.07 |
1,575,231 |
1,683,335 |
31,357,183 |
| Williams Gregg | Director |
Feb 15 '26 |
Buy |
1.06 |
1,866,492 |
1,983,333 |
29,781,952 |
| Williams Gregg | Director |
Jan 27 '26 |
Buy |
1.48 |
1,351,351 |
1,999,999 |
27,915,460 |
| Williams Gregg | Director |
Jan 15 '26 |
Buy |
1.14 |
1,737,765 |
1,983,334 |
26,564,109 |
| Mendelsohn Aaron | Director |
Dec 29 '25 |
Buy |
1.23 |
20,000 |
24,600 |
188,170 |
| Williams Gregg | Director |
Dec 15 '25 |
Buy |
1.14 |
1,737,765 |
1,983,334 |
24,826,344 |
| Williams Gregg | Director |
Nov 15 '25 |
Buy |
1.14 |
1,737,764 |
1,983,333 |
23,088,579 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):